Sentinel surveillance of risk associated with specific allergy vaccination;Sentinel overvågning af risiko for alvorlige reaktioner ved specifik immunterapi: En metode til kvalitetssikring af procedurer med sjældne, men alvorlige bivirkninger

Ugeskrift for Laeger

Volumn 168, Issue 11, 2006, Pages 1122-1124

  Madsen, Flemming F ^a   Frølund, Lars ^a   Christensen, Mogens ^a   Frost, Andreas ^a   Petersen, Ulrik Søes ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE; ALLERGEN;

ALLERGY; CONFIDENCE INTERVAL; GRASS; HEALTH SURVEY; HUMAN; PHYSICIAN; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VACCINATION; ARTICLE; DENMARK; DESENSITIZATION; DRUG SURVEILLANCE PROGRAM; HEALTH CARE QUALITY; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALLERGENS; DENMARK; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; QUALITY ASSURANCE, HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; VACCINES;

EID: 33645112127     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Godolphin W. The role of risk communication in shared decision making. BMJ 2003;327:692-3.
2. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-74.
3. Bousquet J, Lockey R, Malling HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401-5.
4. Malling, HJ, Weeke B. Immunotherapy. Allergy 1993;48 (suppl14):9-35.
5. Malling,HJ. Nyheder. København. Dansk Selskab for allergologi. 2003
6. www.laegemiddelstyrelsen.dk/1024/visLSArtikel.asp?artikelID=1779/ juni 2005
7. Malling. HJ. Bivirkninger Alutard SQ 225 Phleum pratense. København: Dansk Selskab for Allergologi, 2004.
8. Frew, A. J. The UK Immunotherapy Study (UKIS) - an essential study of subcutaneous allergy vaccination. The 5th Symposium on specific allergy. London: Alk-Abelló, 2004: 33
9. www.sst.dk/publ/Publ2004/Vejledning_akutberedskab.pdf/ juni 2005
10. Sismanidis C, Bland M, Poloniecki J. Properties of the cumulative risk-adjusted mortality (CRAM) chart, including the number of deaths before a doubling of the death rate is detected. Med Decis Making 2003;23:242-51.
11. Poloniecki J, Sismanidis C, Bland M et al. Retrospective cohort study of false alarm rates associated with a series of heart operations: the case for hospital mortality monitoring groups. BMJ 2004;328:375-80.
12. Eypasch E, Lefering R, Kum CK et al. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 1995;311:619-20.
13. Greisen G, Betelsen A. Risikoen kan være større, end man skulle tro. Ugeskr Læger 1999;161:6067.
14. Vincent C, Taylor-Adams S, Chapman EJ et al. How to investigate and analyse clinical incidents: Clinical Risk Unit and Association of Litigation and Risk Management protocol. BMJ 2000;320:777.
15. Malling HJ. Clinical safety and efficacy of subcutaneous allergen specific immunotherapy. The 5th Symposium on specific allergy. London: Alk-Abelló, 2004:31
16. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323-32.